Đang chuẩn bị liên kết để tải về tài liệu:
Daclatasvir plus asunaprevir treatment for real-world HCV genotype 1-infected patients in Japan

All-oral combination of direct-acting antivirals could lead to higher sustained virologic response (SVR) in hepatitis C virus (HCV)-infected patients. In the present study, we examined the efficacy and safety of the dual oral treatment with HCV nonstructural protein (NS) 5A inhibitor daclatasvir (DCV) plus HCV NS3/4A inhibitor asunaprevir (ASV) for 24 weeks in real-world HCV genotype 1-infected Japanese individuals. | Daclatasvir plus asunaprevir treatment for real-world HCV genotype 1-infected patients in Japan